Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023.
-
Cash totaled $13.25 (CA$18.1) million by Sept. 30, vs. $13.17 million by August 14, $6.81 million by June 30, and $12.17 million by March 31, 2023.
-
Three and six-month R&D expenses of $4.9 million and $9.57 million, respectively 30.3% and 16.8% increases as per the numbers of the comparable 2022 periods ($3.76 million and $8.19 million.)
-
Three and six-month G&A expenses of $4.24 million and $7.94 million, tuned down 5.1% and 4% as per the numbers of the comparable 2022 periods ($4.47 million and $8.27 million, respectively.)
-
Three and six-month net loss of $8.7 million and $19.47 million, vs. $7.3 million and $16.85 million in the same periods in 2022.
See full Q1 results.
-
Quarterly cash-based operating expenses totaled $9.2 million vs. $8.3 million in the comparable period in 2022.
-
Quarterly cash flows used in operating activities were $8.4 million vs. $10.8 million in the same period in 2022.
-
Quarterly cash flows received from financing activities of $14.9 million vs. $3.4 million in the same period in 2022.
-
Accumulated deficit of $127.74 million by Sept. 30, a 17.8% six-month increase as compared to $108.42 million …